Our Science

We Develop Targeted Antibody Therapeutics That Traffic to Specific Subcellular Organelles in Disease Tissues

We Develop Targeted Antibody
Therapeutics That Traffic to
Specific Subcellular Organelles in Disease Tissues

Lysosome Targeted Antibodies

ER Targeted Antibodies

Golgi Targeted Antibodies

Lorem Ipsum

Pharetra at feugiat. Odio sodales aliquam vel et congue amet porta Donec tincidunt pellentesque libero.

Lysosome Directed Antibodies Enable Degradation of Specific Membrane Protein Drug Targets.

We build customizable multispecific antibodies that interact with the cellular trafficking machinery to improve target degradation. This approach allows improvements in antagonism and the ability to drug the undruggable. We are focusing our internal development initially to Receptor Tyrosine Kinase (RTK) and GPI-anchored drug targets in the oncology space.

Focusing Target Degradation to Specific Cell Types

We focus target degradation in a patient to a specific tissue using a combination of bispecificity and affinity tuning. This approach has the potential to expand the oncology target space to overcome on-target off-tissue adverse side effects.

Partner With Us

Our scaffolds override subcellular trafficking patterns for a target and improve ADC delivery to the lysosome. Reach out to learn more.